The approval was based on a cohort of treatment-naïve patients in the Beamion LUNG-1 trial who had unresectable or metastatic, non-squamous NSCLC with HER2 tyrosine kinase domain mutations.
This press release is not intended for UK mediaHERNEXEOS® (zongertinib tablets) approved based on an objective response rate of 76% (N=72) as ...
The U.S. Food and Drug Administration (FDA) has approved Hernexeos (zongertinib) for adults with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors have specific HER2 ...
Today, the FDA granted accelerated approval to zongertinib (Hernexeos; Boehringer Ingelheim Pharmaceuticals, Inc.) for an expanded indication for adults with unresectable or metastatic non-squamous ...
Investigational BAY 2927088 is an oral, small molecule, tyrosine kinase inhibitor as a potential new targeted therapy for patients with non-small cell lung cancer (NSCLC) harboring HER2 activating ...
The FDA on Friday granted accelerated approval to zongertinib (Hernexeos) for non-squamous non-small cell lung cancer (NSCLC) patients harboring HER2 tyrosine kinase domain (TKD) activating mutations.
Exploring the evolving therapeutic landscape of stage IV lung squamous cell carcinoma: A 13-year single center experience. Evaluating the safety and effectiveness of cemiplimab in combination with ...
What Is Hyrnuo, and Why Does It Matter? Hyrnuo (sevabertinib) is a new oral medicine for adults with advanced nonsquamous non-small-cell lung cancer (NSCLC) carrying a specific genetic change known as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results